Natera Inc at Cowen Health Care Conference (Virtual) Transcript
Good afternoon. I'm Max Masucci, one of the life science and diagnostic tools analyst here at Cowen. It's my pleasure to welcome Natera to our conference this year. Natera is a company that I've been following since 2017, a market leader in NIPT, a major participant in MRD monitoring and also blood-based organ transplant rejection testing. So we're joined by Natera's CEO, Steve Chapman; and CFO, Mike Brophy. Great to see you guys.
Thanks, Max.
Questions & Answers
Awesome. So let's jump in on Signatera first. You provided a snapshot of the cumulative Signatera plus Altera volumes at the time of the Q4 call. There's a [4x-ing] over the past year from [18,000 to north of 76,000]. So I guess to start, is there any way for us to think about what percentage of that [76,000] number includes tests that are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |